BioNTech Consolidates German mRNA Sector with CureVac Acquisition Finalized
18.12.2025 - 16:42:07BioNTech US09075V1026
BioNTech has completed its takeover of CureVac, a move that solidifies its commanding position within Germany’s mRNA therapeutics landscape. By securing nearly 87% of CureVac’s shares, the Mainz-based firm is now positioned to fully integrate its former competitor. The transaction marks a pivotal strategic shift for the company as it moves beyond its pandemic-era foundations.
The acquisition, finalized after the acceptance period concluded at 06:01 CET on December 18, 2025, eliminates a direct rival while granting BioNTech access to a suite of valuable assets. These include CureVac’s proprietary mRNA design platforms, alternative lipid nanoparticle formulations, and additional manufacturing capacity. BioNTech plans to channel these resources directly into its oncology pipeline, which currently Read more...
